$ACA

Arcosa, Inc.

Insider trades

No enriched coverage for $ACA in the last 7 days.

No SEC Form 4 filings for $ACA in the last 30 days.

See all $ACA insider activity →
Low

CRH slips 3.3% as investors appear to keep weighing Arcosa deal financing

CRH plc shares fell 3.3% as investors weighed financing and balance sheet risk around its pending $8.5 billion Arcosa acquisition. CRH’s Q2 release showed higher revenue, profit and margins and it reaffirmed full-year 2026 guidance. An SEC filing cited a new $2.5 billion three-year term loan and expected bridge financing before closing.

Can CRH Gain From Its $8.5 Billion Arcosa Deal Despite Financing Risk?

CRH plans to acquire Arcosa for about $8.5B, with closing expected in Q1 2027 subject to approvals. The deal would add about 35M tons of annual aggregates, targeting over 265M tons U.S. production, and add energy infrastructure exposure. CRH targets $175M annual cost synergies by year three and says the deal should be accretive within 12 months, but notes higher financing and integration risk.

Arcosa, Inc. (ACA): Results of Operations and Financial Condition

Arcosa, Inc. (ACA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh991earningsrelease63020.htm EX-99.1 Document Exhibit 99.1 News Release FOR IMMEDIATE RELEASE Arcosa, Inc. Announces Second Quarter 2026 Results DALLAS, Texas - ARCOSA, Inc. - August 5, 2026: Arcosa, Inc. (NYSE: ACA) (“Arcosa,” the “Company,” “We,” or “Our”), a provid

ACA sentiment & insider activity

Recent ACA coverage spans mergers & acquisitions, market movers and financial news.

What's driving ACA

  • CRH plc shares fell 3.3% as investors weighed financing and balance sheet risk around its pending $8.5 billion Arcosa acquisition. CRH’s Q2 release showed higher revenue, profit and margins and it reaffirmed full-year 2026 guidance. An SEC filing cited a new $2.5 billion three-year term loan and expected bridge financing before closing.

    quiverquant.com · Aug 12, 2026

  • CRH plans to acquire Arcosa for about $8.5B, with closing expected in Q1 2027 subject to approvals. The deal would add about 35M tons of annual aggregates, targeting over 265M tons U.S. production, and add energy infrastructure exposure. CRH targets $175M annual cost synergies by year three and says the deal should be accretive within 12 months, but notes higher financing and integration risk.

    tradingview.com · Aug 7, 2026

  • Q2 operating performance was solid on EBITDA and backlog, but cash flow deteriorated sharply, and the CRH deal remains a key forward catalyst.

    SEC EDGAR 8-K · Aug 5, 2026

  • Arcosa’s stock is directly impacted by a fresh takeover offer, creating immediate deal-spread and takeover-probability trading.

    baystreet.ca · Jun 25, 2026

  • ACA is tied to a potential M&A development; deal-rumor headlines can create high volatility and option-like trading behavior.

    finance.yahoo.com · Jun 24, 2026

alphai scores every news story that mentions ACA with an AI model for sentiment and relevance, and aggregates insider trades from Arcosa, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ACA

Score

Can CRH Gain From Its $8.5 Billion Arcosa Deal Despite Financing Risk?

CRH plans to acquire Arcosa for about $8.5B, with closing expected in Q1 2027 subject to approvals. The deal would add about 35M tons of annual aggregates, targeting over 265M tons U.S. production, and add energy infrastructure exposure. CRH targets $175M annual cost synergies by year three and says the deal should be accretive within 12 months, but notes higher financing and integration risk.

Arcosa, Inc. (ACA): Results of Operations and Financial Condition

Arcosa, Inc. (ACA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh991earningsrelease63020.htm EX-99.1 Document Exhibit 99.1 News Release FOR IMMEDIATE RELEASE Arcosa, Inc. Announces Second Quarter 2026 Results DALLAS, Texas - ARCOSA, Inc. - August 5, 2026: Arcosa, Inc. (NYSE: ACA) (“Arcosa,” the “Company,” “We,” or “Our”), a provid

$CRHHighAI 9/10

CRH to Buy Arcosa, Shares Skid

CRH said it will buy 100% of Arcosa in an all-cash deal for $150 per share, subject to Arcosa shareholder and regulatory approvals. The offer implies a 25% premium to Arcosa’s June 18 60-day VWAP. CRH values Arcosa at about $8.5B enterprise value (11.5x 2026E adj. EBITDA) and expects $175M annual synergies by year three.

Stocks Erase Early Gains as Alphabet and Software Companies Fall

US stocks gave back early gains as software and defense shares fell. Alphabet dropped over 6% after Google DeepMind VP Jumper said to be leaving for Anthropic. Defense names slid after Iran said it made “major progress” with the US on a peace deal. Rates: 10-year Treasury yield rose to 4.489% amid $211B in auctions. Semiconductors and AI stocks led gains; Palantir, Intuit, Oracle fell, while SOXX hit a record.

$CRHHighAI 9/10

CRH To Acquire Arcosa For $150/share, Arcosa Up In Pre-market

CRH plc agreed to acquire Arcosa, Inc. for $150 per share in cash, valuing Arcosa at about $8.5 billion and implying a 25% premium to its 60-day VWAP as of June 18, according to CRH. CRH expects $175 million in annual run-rate cost synergies by year three and accretion within 12 months after closing, targeted for Q1 2027.

$ABBVMed

The Club's top 10 things to watch in the stock market Monday

The newsletter highlights a muted start to the week, with S&P 500 flat and Nasdaq up, and WTI around $76.50. It covers SpaceX’s KeyBanc hold, AbbVie’s $10.9B purchase of Apogee, CRH’s $8.5B Arcosa deal, and analyst moves on Corning, Nucor, Estee Lauder, and semiconductor equipment. It also notes a 20-year Chevron-Microsoft natural gas power deal for a West Texas data center.

Related tickers